Metabolic manipulation in chronic heart failure: Study protocol for a randomised controlled trial

Roger M. Beadle, Lynne K. Williams, Khaild Abozguia, Kiran Patel, Francisco Leyva Leon, Zaheer Yousef, Anton Wagenmakers, Michael P. Frenneaux

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)


Heart failure is a major cause of morbidity and mortality in society. Current medical therapy centres on neurohormonal modulation with angiotensin converting enzyme inhibitors and β-blockers. There is growing evidence for the use of metabolic manipulating agents as adjunctive therapy in patients with heart failure. We aim to determine the effect of perhexiline on cardiac energetics and alterations in substrate utilisation in patients with non-ischaemic dilated cardiomyopathy.
Original languageEnglish
Article number140
Publication statusPublished - 6 Jun 2011


  • Adenosine Triphosphate
  • Cardiac Catheterization
  • Cardiomyopathy, Dilated
  • Cardiovascular Agents
  • Double-Blind Method
  • Drug Monitoring
  • Echocardiography, Doppler
  • Energy Metabolism
  • Great Britain
  • Heart Failure
  • Humans
  • Magnetic Resonance Imaging
  • Magnetic Resonance Spectroscopy
  • Myocardium
  • Perhexiline
  • Phosphocreatine
  • Placebo Effect
  • Prospective Studies
  • Recovery of Function
  • Research Design
  • Stroke Volume
  • Time Factors
  • Treatment Outcome
  • Ventricular Function, Left

Cite this